Serono Symposia International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so participants may form their own judgments, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement, nor a recommendation, on the part of Serono Symposia International Foundation. All presentations solely represent the independent views of the presenters/authors.
The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:
Maria Pia Amato: Declared no potential conflict of interest.
Sharalyn Anderson: Declared no potential conflict of interest.
Giancarlo Comi: Declared receipt of honoraria or consultation fees from Serono Symposia International Foundation, Biogen-Dompé, Novartis, Bayer-Schering, Teva Pharmaceutical Ind. and Sanofi Aventis.
Monica Falautano: Declared no potential conflict of interest.
Mark S. Freedman: Declared receipt of honoraria or consultation fees from Bayer, BiogenIdec, BioMS Merck Serono, Novartis, Sanofi-Aventis, Teva. Declared also to be a member of a Bayer, BioMS Merck Serono, Novartis and Sanofi-Aventis advisory boards or other similar groups.
Urs N. Gamper: Declared no potential conflict of interest.
Ralf Gold: Declared receipt of grants and contracts from Merck Serono, BiogenIdec, Teva, Bayer-Schering, Novartis. Declared receipt of honoraria or consultation fees from Merck Serono, BiogenIdec, Teva, Bayer-Schering, Novartis. Declared also to be a member of Teva, BiogenIdec advisory boards or other similar groups.
Eija Luoto: Declared receipt of honoraria or consultation fees from Serono Symposia International Foundation in 2008.
Xavier Montalban: Declared receipt of honoraria or consultation fees from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Teva and Sanofi-Aventis.
Carlo Pozzilli: Declared receipt of grants and contracts from Merck Serono, Bayer-Schering, Sanofi Aventis. Declared receipt of honoraria or consultation fees from BiogenIdec, Novartis. Declared also to be a member of BiogenIdec, Sanofi Aventis, Bayer-Schering advisory boards or other similar groups.
Gemma Rodríguez Martín: Declared no potential conflict of interest.
Mohammed K. Sharief: Declared receipt of honoraria or consultation fees from Merck Serono Beringer Ingleheim and MSD. Declared also a participation in a Merck Serono’s sponsored speaker’s bureau.
The following faculty has provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA approved (off-label) uses of drugs as of July 22, 2009.
Dawn Langdon
Franco Molteni
Roberta Motta
Amy Perrin Ross
